BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
BioNTech and OncoC4 said gotistobart nearly doubled median overall survival versus standard chemotherapy in previously treated squamous NSCLC in the first median-OS readout from a randomized Phase 3 trial. The result strengthens the drug’s clinical case, but the program remains investigational and the disclosed data come from a non-pivotal stage of the study.
BioNTech and OncoC4 announced that gotistobart produced a median overall-survival result nearly twice that of standard-of-care chemotherapy in patients with squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. This update represents the first median-OS data from stage 1 of PRESERVE-003, a global randomized Phase 3 trial identified as NCT05671510, announced on September 14, 2026.
Gotistobart, also known as BNT316 or ONC-392, is an investigational CTLA-4-targeting immunotherapy. BioNTech and OncoC4 designed it to selectively deplete regulatory T cells within the tumor microenvironment.
The program connects BioNTech and OncoC4 through the jointly developed asset: BNT316 is BioNTech's designation, while ONC-392 is OncoC4's. The clinical opportunity is a previously treated squamous NSCLC population with progression after both immunotherapy and chemotherapy, a setting in which a survival advantage could support later regulatory and commercial development if the broader study confirms it.
The result is not yet a pivotal regulatory outcome. The companies described the readout as coming from the non-pivotal stage 1 portion of a Phase 3 trial.
The next evidence points are the full data presentation, additional results from PRESERVE-003 and any regulatory update. The key questions are whether the survival difference is statistically robust, whether it is accompanied by an acceptable safety profile, and whether the randomized Phase 3 program can reproduce the result in the intended treatment population.
The survival signal moves the clinical and partnering risk to the upside for BNTX, though the pivotal readout remains ahead.
The readout improves the asset’s clinical value because a near-doubling of median overall survival in previously treated squamous NSCLC could strengthen BioNTech’s oncology pipeline and its relationship with OncoC4. The case is not yet directional enough for a dated trade call because the announcement omits the underlying survival figures, statistical detail, safety data and a next event date.
The signal could weaken if the full dataset shows marginal statistical significance, materially worse safety, or failure to reproduce the survival benefit in the pivotal portion of PRESERVE-003.
CoverageSource: GlobeNewswire · Published here MON, SEP 14 · 4:00 AM ET · 2 reports · 1 publisher in this record · latest listed: GlobeNewswire · MON, SEP 14 · 4:16 AM ETHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
BioNTech and OncoC4 report that gotistobart nearly doubled median overall survival versus chemotherapy in a randomized Phase 3 population with disease progression after immunotherapy and chemotherapy.
The evidence remains incomplete because the announcement gives no underlying median-survival figures, hazard ratio, statistical significance or safety results and describes the readout as non-pivotal stage 1 data.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →